The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens
- 12 November 2009
- journal article
- research article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 136 (6) , 803-809
Abstract
Previous studies have suggested that DNA repair enzyme polymorphisms may bear prognostic value in metastatic colorectal carcinoma (MCRC). We prospectively treated 43 MCRC patients with irinotecan-based regimens (XELIRI or IFL). Allelic variants of the XRCC1 gene at codon 399 and XPD gene at codon 751 were analyzed in lymphocyte DNA by PCR–RFLP. Clinical outcome variables: overall survival (OAS), progression-free survival (PFS) and the occurrence of grade 3 or 4 hematological and gastrointestinal (GIS) toxicities were evaluated. In the univariate analysis for OAS (n = 43) only XPD and XRCC1 polymorphisms were significant (P = 0.05 and P = 0.04, respectively). After adjustment for performance status (ECOG = 0, 1 vs. 2) and disease extent (single vs. multiple metastatic site), XRCC1 genotype and performance status retained significance (HR = 2.85, P = 0.04, and HR = 3.19, P = 0.02, respectively). Gln/Gln genotype was associated with the greatest risk of death. Type of presentation (metastatic vs. local disease at first presentation) was the only significant predictor of PFS in the univariate analysis (n = 40, P = 0.003). After adjustment for performance status and disease extent, type of presentation retained its significance (HR = 4.35, P = 0.003). None of the toxicities was associated with these genotypes. XRCC1 genotype independently predicted overall survival in metastatic colorectal carcinoma patients treated with irinotecan-based chemotherapy.Keywords
This publication has 29 references indexed in Scilit:
- Predictive Biomarkers of Chemotherapy Efficacy in Colorectal Cancer: Results From the UK MRC FOCUS TrialJournal of Clinical Oncology, 2008
- Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiationBritish Journal of Cancer, 2008
- XRCC1 and DNA polymerase β in cellular protection against cytotoxic DNA single-strand breaksCell Research, 2008
- Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapyThe Pharmacogenomics Journal, 2007
- XPA A23G, XPC Lys939Gln, XPD Lys751Gln and XPD Asp312Asn polymorphisms, interactions with smoking, alcohol and dietary factors, and risk of colorectal cancerMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2007
- Which Gene is a Dominant Predictor of Response During FOLFOX Chemotherapy for the Treatment of Metastatic Colorectal Cancer, the MTHFR or XRCC1 Gene?Annals of Surgical Oncology, 2006
- A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancerAnnals of Oncology, 2005
- Factors predicting survival in stage IV colorectal carcinoma patients after palliative treatment: A multivariate analysisJournal of Surgical Oncology, 2005
- Systemic Therapy for Colorectal CancerNew England Journal of Medicine, 2005
- Human xeroderma pigmentosum group D gene encodes a DMA helicaseNature, 1993